Last updated on February 2018

A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder


Brief description of study

The purpose of this study is to evaluate the safety and effectiveness of quetiapine in actual clinical settings.

Detailed Study Description

This is a post-marketing use-result survey study required for products in Japan. The investigator will register the patient who have been taking this product for the first time within 14 days after the start of treatment (inclusive of the start day). For each of the registered patients (including withdrawals and dropouts), the investigator will enter the survey data on the case report form.

Clinical Study Identifier: NCT03403790

Contact Investigators or Research Sites near you

Start Over

Astellas Pharma Inc.

Site JP00025
Shiga, Japan
  Connect »

Astellas Pharma Inc.

Site JP00026
Kyoto, Japan
5.71miles
  Connect »